期刊
JOURNAL OF FUNCTIONAL BIOMATERIALS
卷 13, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/jfb13040174
关键词
survey; meropenem; vaborbactam; cefiderocol; intensive care unit; stewardship; multi-drug resistant
Meropenem/vaborbactam and cefiderocol are promising antibacterials against multi-drug resistant gram-negative bacilli. A survey was conducted among infectious disease and intensive care unit physicians of Italian hospitals to gather data on their habits and prescriptions of these drugs. The results showed that both cefiderocol and meropenem/vaborbactam were mostly used as targeted therapy after treatment failure and specialist consultation. The most common multi-drug resistant pathogen in hospitals was Klebsiella pneumoniae carbapenemase-producing bacteria.
Meropenem/vaborbactam (MV) and cefiderocol were recently approved by the Food and Drug Administration and European Medicines Agency and are among the most promising antibacterial in treatment regimens against multi-drug resistant (MDR) gram-negative bacilli. A survey with close-ended questions was proposed to infectious disease (ID) and intensive care unit (ICU) physicians of Piedmont and Valle d'Aosta Region's hospitals. The aim was to collect data about habits and prescriptions of cefiderocol and MV. Twenty-three physicians (11 ID specialists and 12 anesthesiologists) in 13 Italian hospitals took part in the survey. Both cefiderocol and MV were mostly used as target therapy after a previous treatment failure and after ID specialist consult. The most frequent MDR pathogen in hospitals was Klebsiella pneumoniae carbapenemase-producing bacteria (KPC), followed by P. aeruginosa and A. baumannii. MDRs were more frequently isolated in ICU. In conclusion, cefiderocol was used in empiric regimens when A. baumannii was suspected, while MV was more used in suspect of KPC. MV and cefiderocol can be the first option in empiric treatment for critically ill patients in settings with high risk of MDR. The treatment should then be followed by rapid de-escalation when microbiological results are available.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据